The Liquid Biopsy Market focuses on non-invasive tests that detect cancer and other diseases using biomarkers, such as circulating tumor DNA (ctDNA), in blood samples. It is growing due to rising cancer cases, the demand for early detection, advances in genomic technologies, and increased adoption of personalized medicine in oncology.
According to FutureWise analysis, the Liquid Biopsy Market in 2026 is US$11.77 billion, and is expected to reach US$29.45 billion by 2036 at a CAGR of 9.61%. The growing demand for non-invasive diagnostic methods in oncology is boosting the use of liquid biopsies, which enable early cancer detection and real-time treatment monitoring. Advances in circulating tumor DNA (ctDNA), exosome analysis, and next-generation sequencing (NGS) are enhancing the accuracy and application of these methods across different cancer types.
Growth Drivers:
- Rising global prevalence of cancer
- Growing demand for non-invasive diagnostic techniques
- Increasing adoption of personalized and precision medicine
- Advancements in next-generation sequencing (NGS) and molecular diagnostics
- Higher focus on early cancer detection and screening programs
Key Trends:
- Rising adoption of next-generation sequencing (NGS) and AI-powered analytics
- Shift toward early cancer detection and screening solutions
- Increasing use of multi-cancer and pan-cancer assays
- Growth in companion diagnostics and therapy guidance tools
- Expansion of liquid biopsy applications beyond oncology (e.g., transplant monitoring, prenatal testing)
Market Segmentation and Key Players:
The Liquid Biopsy Market is segmented by product into assay kits, instruments, and services; by biomarker type into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and others; by clinical application including early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring; by application into oncology (lung, breast, colorectal, prostate, and other cancers) and non-oncology uses; and by end user such as hospitals, reference laboratories, and academic research centers across major regions. Comprehensive segmentation details are provided in the Segmentation section below.
Major companies operating in the Liquid Biopsy Market include Biocept Inc., Qiagen N.V., and Roche Diagnostics.
Research Methodology:
The Liquid Biopsy Market report by FutureWise Research is developed using a combination of secondary research (industry reports, company filings, databases, and publications) and primary research (interviews with industry experts and key stakeholders). The methodology includes data triangulation, market sizing through quantitative analysis, and forecasting based on current trends, drivers, challenges, and competitive landscape assessment to ensure accurate and reliable market insights.